Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Key Takeaway: Merck's Tulisokibart has met its primary and key secondary endpoints in the Phase 3 ATLAS-UC study focused on patients with moderately to severely active ulcerative colitis. This development marks a significant milestone in the treatment of this condition. Further details on the implications of these results were not provided.